Neuraxis, Inc.
NRXSNeuraxis, Inc. (NRXS) is a biotechnology company focused on developing neurotherapeutic products targeting neurological and psychiatric disorders. The company specializes in creating innovative treatments leveraging its expertise in neurostimulation and neurotechnology to address unmet medical needs in neurological conditions.
Company News
NeurAxis, Inc. (NYSE American: NRXS), a medical technology company specializing in neuromodulation therapies, announced it will report Q1 2026 financial results on May 12, 2026, before market open, followed by a conference call at 9:00 am ET. The company commercializes IB-Stim, its proprietary Percutaneous Electrical Nerve Field Stimulation (PENF...
NeurAxis received FDA 510(k) clearance for its percutaneous electrical nerve field stimulation (PENFS) technology to treat functional dyspepsia and related nausea symptoms in patients aged 8 years and older, marking the first FDA approval for this condition in adults.
NeurAxis, Inc. will report its Q1 2025 financial results on May 12, 2025, before market open, and host a conference call on the same day at 9:00 am ET to review the results.
NeurAxis, a medical technology company, will report its Q4 and fiscal year 2024 financial results on March 20, 2025, and host a conference call to discuss the results.
NeurAxis, a medical technology company, announced that its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim, has received medical policy coverage from a prominent insurer with approximately 5.1 million members across 13 states.
